Inhibikase Therapeutics Inc. (IKT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Inhibikase Therapeutics I... (IKT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.75

0.09 (3.38%)

At close: Jan 15, 2025, 2:43 PM

undefined% (undefined)

Bid	2.72
Market Cap	190.75M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.12
PE Ratio (ttm)	-0.88
Forward PE	n/a
Analyst	Buy

Ask	2.78
Volume	54,173
Avg. Volume (20D)	338,983
Open	2.70
Previous Close	2.66
Day's Range	2.68 - 2.83
52-Week Range	1.12 - 4.20
Beta	undefined

About IKT

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 23, 2020

Employees 8

Stock Exchange NASDAQ

Ticker Symbol IKT

Website https://www.inhibikase.com

Analyst Forecast

According to 2 analyst ratings, the average rating for IKT stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 136.36% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-13.14%

Inhibikase Therapeutics shares are trading lower. ... Unlock content with Pro Subscription

2 months ago · Source

+3.6%

Inhibikase Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced an $8 price target.

News

1 month ago · seekingalpha.com

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims ...